Uhura Bionics Tests Everyday Wearables for Life Without a Voice Box
Uhura Bionics is selling two wearables for laryngectomees, people who have had their voice boxes removed. The basic model costs $500, and the high-end version costs $1,500 and is called Whitney, after singer Whitney Houston. TechCrunch
The company was launched in 2023 by Konrad Zieliński, who lost his voice to cancer while a student at the University of Warsaw. He later completed a PhD focused on bionic systems for laryngectomees, engineered systems that take over some voice box function. He underwent a total laryngectomy, removal of the entire larynx. After that surgery, he could still communicate using existing solutions.
Uhura was selected as one of TechCrunch Disrupt 2026's Battlefield 200. Disrupt 2026 is scheduled for October 13-15 at Moscone West in San Francisco. TechCrunch The company's Startup Battlefield listing describes its product as a bionic larynx for singing, laughing and translating emotions. TechCrunch
Both devices are sold as wellness devices paid out of pocket, with no prescription or insurance claim. Uhura is seeking Class I medical device classification, the lowest-risk category, in Europe and later in the U.S. Zieliński estimates the market size for devices serving laryngectomees at about $2 billion.
He knows the problem firsthand. He said he hopes laryngectomees will use Whitney like people with poor eyesight use glasses. The plan is daily wear, not clinical intervention. Uhura plans to add higher-pitched voice options for women to its devices. It also plans to add personalization features so users do not all sound alike.
Zieliński plans to take Whitney onstage at TechCrunch Disrupt and at SF Tech Week in October, where he will sing onstage with Whitney's help. Singing is demanding. It requires continuous pitch control, timing and breath coordination that phrase-based speech aids, which play back short pre-set phrases, do not attempt.
The broader context here is the choice to ship first as wellness hardware while pursuing clearance in parallel. Wellness classification lowers friction to iteration and deployment, but leaves pricing, support and liability with the user. Class I in Europe would open formal distribution and reimbursement, or payment through insurance, without the evidence burden of higher-risk classes. The $500 and $1,500 price points read as an attempt to find where out-of-pocket tolerance sits while that regulatory work proceeds.
In my view, the detail worth watching is voice identity. Default synthetic voices tend to converge, and users notice. Gendered pitch options and per-user personalization address adoption directly, because a voice is social infrastructure. People accept a prosthetic faster when it stops announcing itself. If Uhura can make a wearable that handles conversational speech plus laughing and singing without forcing every user through the same vocal timbre, daily wear becomes plausible. That would expand what assistive voice hardware is expected to do.
Looking ahead, the upside is straightforward. A laryngectomee who can talk, laugh and sing in public with a familiar device regains more than intelligibility.
